Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study

Abstract Previously, we found that patients with estrogen receptor (ER)-positive, HER2-low breast cancer are resistant to neoadjuvant chemotherapy (NACT) and have worse outcomes than those who achieve pathological complete response (pCR) after NACT. This study aimed to investigate the prognosis and...

Full description

Bibliographic Details
Published in:Scientific Reports
Main Authors: Lingfeng Tang, Linshan Jiang, Xiujie Shu, Yudi Jin, Haochen Yu, Shengchun Liu
Format: Article
Language:English
Published: Nature Portfolio 2024-05-01
Subjects:
Neoadjuvant chemotherapy
Breast cancer
Estrogen receptor
HER2-low
Prognosis
Online Access:https://doi.org/10.1038/s41598-024-62592-0

Internet

https://doi.org/10.1038/s41598-024-62592-0

Similar Items